Clinical Trials Browser

Lymphatic Metastasis, Melanoma

Melanoma, Skin Neoplasms

Melanoma, Neoplasm Metastasis, Neoplasms, Skin Diseases, Skin Neoplasms

Melanoma, Skin Neoplasms

Carcinoma, Non-Small-Cell Lung, Glioma, Melanoma, Thyroid Neoplasms

Uveal Melanoma, Melanoma, Colorectal Neoplasms

Brain Neoplasms, Melanoma

Brain Diseases, Brain Neoplasms, Carcinoma, Non-Small-Cell Lung, Melanoma, Neoplasms, Central Nervous System Neoplasms

Brain Neoplasms, Melanoma

Melanoma, Neoplasms

Brain Neoplasms, Melanoma, Neoplasm Metastasis

Brain Neoplasms, Melanoma

Melanoma, Hereditary Sensory and Autonomic Neuropathies

Melanoma, Neoplasm Metastasis

Brain Neoplasms, Melanoma

Brain Neoplasms, Melanoma

Melanoma, Neoplasms

Melanoma, Neoplasm Metastasis, Skin Diseases, Skin Neoplasms

Clinical Trials

Testing Treatment With Encorafenib and Binimetinib Before Surgery for Melanoma With Lymph Node Involvement

PORTSIDE

Adjuvant Therapy Based on Pathologic Response After Neoadjuvant Encorafenib Binimetinib in Melanoma

COLUMBUS

Adaptive BRAF-MEK Inhibitor Therapy for Advanced BRAF Mutant Melanoma

A Study to Learn About the Study Medicine Called PF-07799933 in People With Advanced Solid Tumors With BRAF Alterations.

Study of IDE196 in Patients With Solid Tumors Harboring GNAQ/11 Mutations or PRKC Fusions

Nivolumab With Trametinib and Dabrafenib, or Encorafenib and Binimetinib in Treating Patients With BRAF Mutated Metastatic or Unresectable Stage III-IV Melanoma

A FIH Study of PF-07284890 in Participants With BRAF V600 Mutant Solid Tumors With and Without Brain Involvement

ENCEFALO

Binimetinib and Imatinib for Unresectable Stage III-IV KIT-Mutant Melanoma

EBIN

SuRage-EB

MK3475-C01

EBRAIN-MEL

NAUTILUS: OKI-179 Plus Binimetinib in Patients with Advanced Solid Tumors in the RAS Pathway (Phase 1b) and NRAS-mutated Melanoma (Phase 2)

Binimetinib and Nivolumab for the Treatment of Locally Advanced Unresectable or Metastatic BRAF V600 Wildtype Melanoma

Bioequivalence Binimetinib 3 x 15 mg and 45 mg Formulations

SECOMBIT

BEPCOME-MB

QUAD01

LOGIC-2

A Phase II Study of Single Agent MEK162 in Patients With Advanced Melanoma

CELEBRATE

COLUMBUS-AD

MEMBRAINS

POLARIS

Study of the Combination of Binimetinib and Encorafenib in Adolescent Patients With Unresectable or Metastatic BRAF V600-mutant Melanoma

Hepatic Impairment Study of Encorafenib in Combination With Binimetinib in BRAF Melanoma

Relative Bioavailability of Binimetinib 3 x 15 mg and 45 mg Formulations

PREMIUM

Study Comparing the Efficacy of MEK162 Versus Dacarbazine in Unresectable or Metastatic NRAS Mutation-positive Melanoma

Intermittent LGX818 and MEK162 in Treating Patients With Metastatic Melanoma Who Have BRAFV600 Mutations